Pharmacokinetic–Pharmacodynamic Correlation Analysis of Rhodiola crenulata in Rats with Myocardial Ischemia
-
Published:2024-05-07
Issue:5
Volume:17
Page:595
-
ISSN:1424-8247
-
Container-title:Pharmaceuticals
-
language:en
-
Short-container-title:Pharmaceuticals
Author:
Jia Zhixin1ORCID, Zou Guoming2, Xie Yongyan2, Zhang Enning3, Yimingjiang Mureziya4ORCID, Cheng Xianlong1, Fang Cong2ORCID, Wei Feng1ORCID
Affiliation:
1. National Institutes for Food and Drug Control, Beijing 100050, China 2. Jiangxi University of Chinese Medicine, Nanchang 330004, China 3. School of Life Science, Beijing University of Chinese Medicine, Beijing 102401, China 4. School of Chinese Materia Medical, Beijing University of Chinese Medicine, Beijing 102401, China
Abstract
The pharmacokinetics (PK) of Rhodiola crenulata in rats were studied, and pharmacokinetic–pharmacodynamic (PK-PD) correlation analysis was performed to elucidate their time–concentration–effect relationship. The myocardial ischemia model was made with pituitrin. Rats were divided into sham operation, sham operation administration, model, and model administration groups (SG, SDG, MG, and MDG, respectively; n = 6). Blood was collected from the fundus venous plexus at different time points after oral administration. The HPLC-QQQ-MS/MS method was established for the quantification of five components of Rhodiola crenulata. CK, HBDH, SOD, LDH, and AST at different time points were detected via an automatic biochemical analyzer. DAS software was used to analyze PK parameters and PK-PD correlation. The myocardial ischemia model was established successfully. There were significant differences in the PK parameters (AUC0–t, AUC0–∞, Cmax) in MDG when compared with SDG. Two PD indicators, CK and HBDH, conforming to the sigmoid-Emax model, had high correlation with the five components, which indicated a delay in the pharmacological effect relative to the drug concentration in plasma. The difference in the PK parameters between modeled and normal rats was studied, and the time–concentration–effect of composition and effect indicators were investigated. This study can provide reference for the rational clinical application of Rhodiola crenulata and for related studies of other anti-myocardial ischemia drugs.
Funder
Beijing Municipal Natural Science Foundation Doctoral Research Foundation of Jiangxi University of Chinese Medicine National Key R&D Program of China Jiangxi University of Chinese Medicine School-level Science and Technology Innovation Team Development Program
Reference43 articles.
1. Managing Stable Ischemic Heart Disease;Antman;N. Engl. J. Med.,2020 2. Association Between High-Sensitivity Cardiac Troponin, Myocardial Ischemia, and Revascularization in Stable Coronary Artery Disease;Rajkumar;J. Am. Coll. Cardiol.,2022 3. Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction. Universal definition of myocardial infarction;Thygesen;J. Am. Coll. Cardiol.,2007 4. Pu, W.L., Zhang, M.Y., Bai, R.Y., Sun, L.K., Li, W.H., Yu, Y.L., Zhang, Y., Song, L., Wang, Z.X., and Peng, Y.F. (2020). Anti-inflammatory effects of Rhodiola rosea L.: A review. Biomed. Pharmacother., 121. 5. Rhodiola rosea: A Therapeutic Candidate on Cardiovascular Diseases;Chen;Oxid. Med. Cell Longev.,2022
|
|